Kiadis Pharma News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.11.20	Kiadis-Aktie +249 Prozent: Sanofi will Krebsmedikamente-Spezialisten Kiadis kaufen - Sanofi-Aktie im Plus (AWP) Der Pharmakonzern Sanofi will das auf Krebsmedikamente spezialisierte niederländische Unternehmen Kiadis für mehr als 300 Millionen Euro kaufen.» mehr
02.11.20	Sanofi kauft niederländisches Unternehmen Kiadis für 308 Mio EUR (Dow Jones)
17.08.20	Kiadis collaborates with premier Dutch institutions to apply K-NK-cell technology for the development of a novel COVID-19 therapy (GlobeNewswire)
06.05.20	Kiadis Pharma announces U.S. FDA approval to start NK-REALM Phase 2 clinical trial for natural killer (NK) cell therapy produced with PM21 (GlobeNewswire)
30.04.20	Kiadis Pharma announces closing of two private placements totalling €17 million (GlobeNewswire)
30.04.20	Kiadis Pharma announces annual results for the year ended December 31, 2019 (GlobeNewswire)
10.03.20	Kiadis Pharma announces new data on ex-vivo FC21 expanded NK-cell therapy in 13 patients with relapsed/refractory acute myeloid leukemia will be presented at the European Society for Blood and Marrow (GlobeNewswire)
04.03.20	Kiadis Pharma to present at BioCapital Europe 2020 (GlobeNewswire)
26.02.20	Kiadis Pharma announces FDA clearance of clinical study by The Ohio State University in R/R AML with off-the-shelf NK cells from universal donors (GlobeNewswire)
11.12.19	Kiadis Pharma announces change to management board (GlobeNewswire)
25.11.19	Kiadis Pharma to present at the 2019 Piper Jaffray 31st Annual Healthcare Conference (GlobeNewswire)
31.01.18	Last Patient Dosed with ATIR101™ in the Phase II ‘008’ Clinical Trial (Businesswire)
16.01.18	Kiadis Pharma proposes former Cipla CEO Subhanu Saxena as new Supervisory Board member (Businesswire)
05.01.18	Kiadis Pharma to Present at Biotech Showcase™ Annual Conference on January 8, 2018 (Businesswire)
06.12.17	Kiadis Pharma to lease existing commercial manufacturing facility in The Netherlands (Businesswire)
04.12.17	First Patient Enrolled in Phase 3 Trial for ATIR101™ in Adult Patients with Blood Cancer (Businesswire)
08.11.17	Kiadis Pharma Announces Participation at Three Upcoming Investor Events (Businesswire)
10.10.17	Kiadis Pharma Raises €18.0 Million in a Private Placement of 2.25 Million New Shares (Businesswire)
09.10.17	Kiadis Pharma Launches a Private Placement of Approximately 2.25 Million New Shares (Businesswire)
29.09.17	Kiadis Pharma appoints Dr. Andrew Sandler as Chief Medical Officer (Businesswire)
27.09.17	Kiadis Pharma Provides Update on the Marketing Authorization Application Process for ATIR101™ in Europe (Businesswire)
20.09.17	Kiadis Pharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ATIR101™ (Businesswire)
19.09.17	Kiadis Pharma: Cellular Immunotherapy Presentation at 4th Cell and Gene Therapy Conference Review of Phase I and II ATIR101™ data (Businesswire)
05.09.17	Kiadis Pharma Appoints Karl Hård as Head of Investor Relations and Communications (Businesswire)
25.08.17	Kiadis Pharma Announces Financial Results for the Six Months Ended June 30, 2017 (Businesswire)
17.08.17	Kiadis Pharma obtains up to €15 million debt financing from Kreos Capital (Businesswire)
26.07.17	Kiadis Pharma proposes former Actelion COO Otto Schwarz as new Supervisory Board member (Businesswire)
22.05.17	Kiadis to Host Key Opinion Leader Meeting on Addressing the Risks of Haloidentical HSCT in Blood Cancer (Businesswire)
26.04.17	DGAP-News: Kiadis Pharma N.V. (EQS Group)
31.03.17	DGAP-News: Kiadis Pharma N.V. (EQS Group)
28.03.17	DGAP-News: Kiadis Pharma N.V. (EQS Group)
20.03.17	DGAP-News: Kiadis Pharma N.V. (EQS Group)
13.03.17	Kiadis Pharma to present ATIR101™ Phase II trial data in Late Breaking Abstract at the International Society for Cellular Therapy (ISCT) 2017 Annual Meeting (Businesswire)
06.02.17	DGAP-News: Kiadis Pharma N.V. (EQS Group)
21.12.16	DGAP-News: Kiadis Pharma N.V. (EQS Group)
21.12.16	DGAP-News: Kiadis Pharma gibt Update zur Studie (CR-AIR-008) mit zweiter Dosis ATIR101(TM) (dpa-afx)
21.12.16	Kiadis Pharma provides update on second dose trial (CR-AIR-008) with ATIR101™ (Businesswire)
21.12.16	Kiadis Pharma provides update on second dose trial (CR-AIR-008) with ATIR101™ (Businesswire)
15.12.16	DGAP-News: Kiadis Pharma N.V. (EQS Group)
15.12.16	DGAP-News: Kiadis Pharma gibt Start der klinischen Phase-I/II-Studie mit ATIR201(TM) zur Behandlung von Thalassämie bekannt (dpa-afx)
15.12.16	Kiadis Pharma announces initiation of a Phase I/II clinical trial with ATIR201™ for thalassemia (Businesswire)
15.12.16	Kiadis Pharma announces initiation of a Phase I/II clinical trial with ATIR201™ for thalassemia (Businesswire)
08.12.16	DGAP-News: Kiadis Pharma N.V. (EQS Group)
08.12.16	DGAP-News: Geplante Änderungen im Management Team von Kiadis Pharma (dpa-afx)
08.12.16	Kiadis Pharma N.V.: Planned Management Team Changes (Businesswire)
06.12.16	DGAP-News: Kiadis Pharma N.V. (EQS Group)
06.12.16	DGAP-News: Kiadis Pharma präsentiert positive 1-Jahres-Follow-up-Ergebnisse aus seiner pivotalen Phase-II-Studie mit ATIR101(TM) (dpa-afx)
03.11.16	One year data from Kiadis Pharma’s ongoing Phase II trial with ATIR101™ will be presented at the American Society of Hematology 2016 Annual Meeting (Businesswire)
26.08.16	DGAP-News: Kiadis Pharma gibt Finanzergebnisse für das zum 30. Juni 2016 endende erste Halbjahr bekannt (dpa-afx)
26.08.16	DGAP-News: Kiadis Pharma N.V. (EQS Group)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Geberit	545.60	2.17 %	K V
Sika	235.80	1.51 %	K V
CieFinRichemont	127.65	1.43 %	K V
Part Grp Hldg	1’299.50	1.33 %	K V
Holcim	91.86	1.15 %	K V
Roche Hldg G	254.50	-0.66 %	K V
Lonza Grp	525.00	-0.72 %	K V
Sonova Hldg	297.70	-1.03 %	K V
Alcon	77.12	-1.20 %	K V
Swiss Life Hldg	690.40	-4.69 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Kiadis Pharma N.V.

Aktien Top/Flop

Meistgelesene Nachrichten